Skip to main content
NCBI home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2002 Jan;10(1):19–22.

Isolated systolic hypertension as a treatable risk factor

PA van Zwieten
PMCID: PMC2499667  PMID: 25696028

Abstract

Isolated systolic hypertension (ISH) is characterised by elevated systolic (SBP) and somewhat lowered diastolic blood pressure (DBP). ISH occurs predominantly in elderly hypertensives as a result of aortic stiffness, which increases with age. Elevated SBP and even more so widened pulse pressure (PP=SBP-DBP) are recognised as important risk factors for stroke and ischaemic heart disease. ISH therefore requires consistent drug therapy, combined with lifestyle advice. It is important to lower SBP without reducing DBP too much, in order to avoid a further widening of the PP.

Large-scale intervention studies (SHEP, SYST-EUR, SYST-China, and INSIGHT) have demonstrated that thiazide diuretics and calcium antagonists are the drugs of choice to protect against stroke and MI. ACE inhibitors, AT1-blockers and omapatrilate may be considered because of their haemodynamic effects and their additional benefit in patients with heart failure or diabetes. Nitrates and NO-donors reduce SBP more than DBP because of their effects on the large conduit arteries. Spironolactone is of potential interest since it may reduce aortic stiffness.

Keywords: aortic stiffness, calcium antagonists, isolated systolic hypertension (ISH), pulse pressure (PP), SHEP-study, SYST-EUR study

Full text

PDF
19

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amery A., Fagard R., Guo C., Staessen J., Thijs L. Isolated systolic hypertension in the elderly: an epidemiologic review. Am J Med. 1991 Mar;90(3A):64S–70S. doi: 10.1016/0002-9343(91)90441-y. [DOI] [PubMed] [Google Scholar]
  2. Aviv A. Hypothesis: pulse pressure and human longevity. Hypertension. 2001 Apr;37(4):1060–1066. doi: 10.1161/01.hyp.37.4.1060. [DOI] [PubMed] [Google Scholar]
  3. Brown M. J., Castaigne A., de Leeuw P. W., Mancia G., Palmer C. R., Rosenthal T., Ruilope L. M. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000 May;35(5):1038–1042. doi: 10.1161/01.hyp.35.5.1038. [DOI] [PubMed] [Google Scholar]
  4. Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull. 1994 Apr;50(2):272–298. doi: 10.1093/oxfordjournals.bmb.a072892. [DOI] [PubMed] [Google Scholar]
  5. Farsang C., Garcia-Puig J., Niegowska J., Baiz A. Q., Vrijens F., Bortman G. The efficacy and tolerability of losartan versus atenolol in patients with isolated systolic hypertension. Losartan ISH Investigators Group. J Hypertens. 2000 Jun;18(6):795–801. doi: 10.1097/00004872-200018060-00019. [DOI] [PubMed] [Google Scholar]
  6. Forette F., Seux M. L., Staessen J. A., Thijs L., Birkenhäger W. H., Babarskiene M. R., Babeanu S., Bossini A., Gil-Extremera B., Girerd X. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998 Oct 24;352(9137):1347–1351. doi: 10.1016/s0140-6736(98)03086-4. [DOI] [PubMed] [Google Scholar]
  7. Heesen W. F., Beltman F. W., Smit A. J., May J. F., de Graeff P. A., Muntinga J. H., Havinga T. K., Schuurman F. H., van der Veur E., Meyboom-de Jong B. Reversal of pathophysiologic changes with long-term lisinopril treatment in isolated systolic hypertension. J Cardiovasc Pharmacol. 2001 May;37(5):512–521. doi: 10.1097/00005344-200105000-00003. [DOI] [PubMed] [Google Scholar]
  8. Kannel W. B., Wolf P. A., McGee D. L., Dawber T. R., McNamara P., Castelli W. P. Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA. 1981 Mar 27;245(12):1225–1229. [PubMed] [Google Scholar]
  9. Kaplan N. M. New issues in the treatment of isolated systolic hypertension. Circulation. 2000 Sep 5;102(10):1079–1081. doi: 10.1161/01.cir.102.10.1079. [DOI] [PubMed] [Google Scholar]
  10. Kostis J. B., Davis B. R., Cutler J., Grimm R. H., Jr, Berge K. G., Cohen J. D., Lacy C. R., Perry H. M., Jr, Blaufox M. D., Wassertheil-Smoller S. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997 Jul 16;278(3):212–216. [PubMed] [Google Scholar]
  11. Lim P. O., Jung R. T., MacDonald T. M. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999 Nov;48(5):756–760. doi: 10.1046/j.1365-2125.1999.00070.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Liu L., Wang J. G., Gong L., Liu G., Staessen J. A. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998 Dec;16(12 Pt 1):1823–1829. doi: 10.1097/00004872-199816120-00016. [DOI] [PubMed] [Google Scholar]
  13. Messerli F. H., Grossman E., Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998 Jun 17;279(23):1903–1907. doi: 10.1001/jama.279.23.1903. [DOI] [PubMed] [Google Scholar]
  14. Nielsen W. B., Vestbo J., Jensen G. B. Isolated systolic hypertension as a major risk factor for stroke and myocardial infarction and an unexploited source of cardiovascular prevention: a prospective population-based study. J Hum Hypertens. 1995 Mar;9(3):175–180. [PubMed] [Google Scholar]
  15. Safar M. E., Blacher J., Mourad J. J., London G. M. Stiffness of carotid artery wall material and blood pressure in humans: application to antihypertensive therapy and stroke prevention. Stroke. 2000 Mar;31(3):782–790. doi: 10.1161/01.str.31.3.782. [DOI] [PubMed] [Google Scholar]
  16. Safar M. E., London G. M. Therapeutic studies and arterial stiffness in hypertension: recommendations of the European Society of Hypertension. The Clinical Committee of Arterial Structure and Function. Working Group on Vascular Structure and Function of the European Society of Hypertension. J Hypertens. 2000 Nov;18(11):1527–1535. doi: 10.1097/00004872-200018110-00001. [DOI] [PubMed] [Google Scholar]
  17. Staessen J. A., Fagard R., Thijs L., Celis H., Arabidze G. G., Birkenhäger W. H., Bulpitt C. J., de Leeuw P. W., Dollery C. T., Fletcher A. E. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997 Sep 13;350(9080):757–764. doi: 10.1016/s0140-6736(97)05381-6. [DOI] [PubMed] [Google Scholar]
  18. Staessen J. A., Gasowski J., Wang J. G., Thijs L., Den Hond E., Boissel J. P., Coope J., Ekbom T., Gueyffier F., Liu L. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000 Mar 11;355(9207):865–872. doi: 10.1016/s0140-6736(99)07330-4. [DOI] [PubMed] [Google Scholar]
  19. Tonkin A., Wing L. Management of isolated systolic hypertension. Drugs. 1996 May;51(5):738–749. doi: 10.2165/00003495-199651050-00003. [DOI] [PubMed] [Google Scholar]
  20. Wilkinson I. B., Webb Christison D. J., Cockcroft J. R. Isolated systolic hypertension: a radical rethink. It's a risk factor that needs treatment, especially in the over 50s. BMJ. 2000 Jun 24;320(7251):1685–1685. doi: 10.1136/bmj.320.7251.1685. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES